Atossa Therapeutics Secures Rare Pediatric Disease Designation for (Z)-Endoxifen in McCune-Albright Syndrome

Event summary

  • FDA granted Rare Pediatric Disease (RPD) designation to (Z)-endoxifen for treating McCune-Albright Syndrome (MAS) in females.
  • RPD designation qualifies Atossa for a Priority Review Voucher (PRV) upon approval, potentially worth $100–$205 million.
  • Atossa participated in the FD/MAS Alliance Research Priorities Workshop to shape the research agenda for MAS.
  • (Z)-endoxifen is a potent SERM/D with potential to modulate estrogen-driven disease manifestations in MAS.

The big picture

Atossa Therapeutics is expanding the potential of its lead candidate, (Z)-endoxifen, beyond oncology into rare pediatric diseases. The RPD designation for McCune-Albright Syndrome highlights the growing focus on addressing unmet medical needs in rare and serious pediatric conditions. The strategic collaboration with the FD/MAS Alliance underscores Atossa's commitment to engaging with the clinical and patient community to accelerate therapeutic development.

What we're watching

Regulatory Pathway
How the RPD designation will accelerate the development and approval process for (Z)-endoxifen in MAS.
Commercial Potential
Whether the potential PRV can offset development costs and create non-dilutive value for Atossa.
Clinical Strategy
The pace at which Atossa can advance (Z)-endoxifen through clinical trials for MAS and other indications.